Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

482
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
482
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

755
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
755
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

267
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
267
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.4K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.4K
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

506
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
506

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential impact on cholesterol goal achievement and predicted cardiovascular risk by the addition of ezetimibe and bempedoic acid on top of statins: a simulation from the SANTORINI study.

American journal of preventive cardiology·2026
Same author

Lipid-lowering therapy after finding high Lp(a)-adding ezetimibe or intensifying statin treatment?

Journal of clinical lipidology·2026
Same author

Genetic determinants of childhood blood pressure and heart rate in relation to adult health outcomes: the consortium of childhood blood pressure.

European heart journal·2026
Same author

Brain magnetic resonance imaging biomarkers for future frailty; sub-study of FINGER trial.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Lipoprotein(a) levels in Finnish adults: distribution and associations with other cardiovascular risk factors and their awareness and control.

Lipids in health and disease·2026
Same author

Mechanistic explanation for the different statin response according to APOE genotypes.

British journal of clinical pharmacology·2026

Related Experiment Video

Updated: Feb 25, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K

Ezetimibe alone for over 75 years old as a primary prevention to decrease cardiovascular events.

Alpo Vuorio1,2, Petri T Kovanen3, Timo Strandberg4,5

  • 1Mehiläinen, Aviapolis Health Center, Vantaa, Finland.

Annals of Medicine
|February 24, 2026
PubMed
Summary
This summary is machine-generated.

The EWTOPIA 75 study shows ezetimibe reduces atherosclerotic cardiovascular disease (ASCVD) events in older adults without prior heart disease. This cholesterol absorption inhibitor may offer benefits due to age-related changes and a favorable side effect profile.

Keywords:
ASCVDAbsorptionNPC1L1 genecholesterolezetimibeold

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.8K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Related Experiment Videos

Last Updated: Feb 25, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.8K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Area of Science:

  • Cardiology
  • Geriatrics
  • Pharmacology

Background:

  • Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality, particularly in older populations.
  • Cholesterol management is crucial, but statin therapy may not be suitable or sufficient for all individuals, especially the elderly.
  • The EWTOPIA 75 study investigated ezetimibe's efficacy in primary ASCVD prevention in individuals aged 75 years and older.

Purpose of the Study:

  • To evaluate the effectiveness of ezetimibe monotherapy in reducing ASCVD events in elderly individuals without a history of coronary artery disease.
  • To explore potential mechanisms underlying ezetimibe's benefit in this specific demographic.
  • To inform clinical guidelines for dyslipidemia management in older adults.

Main Methods:

  • The EWTOPIA 75 study involved participants aged 75 years or older without established ASCVD.
  • Ezetimibe was administered as a monotherapy to assess its impact on ASCVD event risk.
  • The study design focused on primary prevention outcomes.

Main Results:

  • Ezetimibe therapy demonstrated a reduction in the risk of ASCVD events in the target population.
  • The observed benefits may be linked to increased cholesterol absorption efficiency with age and ezetimibe's effect on non-high-density lipoprotein cholesterol (non-HDL-C).
  • Ezetimibe may slow or stabilize the atherosclerotic process even in the absence of clinical ASCVD.

Conclusions:

  • Ezetimibe monotherapy is effective in reducing ASCVD risk in individuals aged 75 and older without prior coronary artery disease.
  • Age-related increases in cholesterol absorption may enhance ezetimibe's efficacy in this population.
  • Ezetimibe's favorable safety profile and potential for better adherence warrant consideration in primary ASCVD prevention for the elderly.